Page 0026

LIVINGLIVING

The new Accu-Chek Solo micro pump system.

SINGULAR SENSATION

The Accu-Chek Solo patch pump from Roche, an

overview by Professor Nick Oliver from Imperial

College London*.

T

he cornerstone of

Roche's approach

to diabetes care is

integrated personalised

diabetes management.

As with other diabetes technology

companies, it keeps up with the times by

introducing new products into its diabetes

portfolio. Currently available only in some

clinics before a wider release, its newest

is a nifty little patch pump called the Solo.

Professor Nick Oliver, in a presentation

he gave in February 2020 entitled Insulin

Delivery Today and in the Future -

Opportunities and Challenges, pointed

out that satisfaction is vital in pump

uptake. He says, "There are many factors

that can affect someone's satisfaction.

Some factors involved may be less about

the device itself than, say, skin sensitivities

and irritations."

The fact remains that pumps have

been proven to lower HbA1c by 0.5 mmol

almost across the board and have been

proven to reduce severe hypos by 55%.

So, despite some gripes, in his view pump

uptake should be encouraged.

It is also true that in the UK we are

at about 16% uptake of pump usage in

the group of people with diabetes who

qualify one, whereas in the US they are

much more widely used, as many as

KIT

REPORT

Index

  1. Page 0001
  2. Page 0002
  3. Page 0003
  4. Page 0004
  5. Page 0005
  6. Page 0006
  7. Page 0007
  8. Page 0008
  9. Page 0009
  10. Page 0010
  11. Page 0011
  12. Page 0012
  13. Page 0013
  14. Page 0014
  15. Page 0015
  16. Page 0016
  17. Page 0017
  18. Page 0018
  19. Page 0019
  20. Page 0020
  21. Page 0021
  22. Page 0022
  23. Page 0023
  24. Page 0024
  25. Page 0025
  26. Page 0026
  27. Page 0027
  28. Page 0028
  29. Page 0029
  30. Page 0030
  31. Page 0031
  32. Page 0032
  33. Page 0033
  34. Page 0034
  35. Page 0035
  36. Page 0036
  37. Page 0037
  38. Page 0038

Related Issues